Cardiff Oncology Inc (CRDF) FinancialsCRDFCardiff Oncology Inc

Evaluating the bottom line, Cardiff Oncology, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9245.19%, while the net margin is -8876.92%. These profitability ratios, combined with a Return on Equity (ROE) of -94.14%, provide a clear picture of how effectively CRDF converts its operational activities into shareholder value.

In the context of the broader market, CRDF competes directly with industry leaders such as ECOR and LNSR. With a market capitalization of $58.76M, it holds a significant position in the sector. When comparing efficiency, CRDF's gross margin of 100.00% stands against ECOR's 88.47% and LNSR's 50.91%. Such benchmarking helps identify whether Cardiff Oncology, Inc. is trading at a premium or discount relative to its financial performance.

Cardiff Oncology has shown a gross margin of 100% consistently, but the net income remains negative, with a net loss of -9.24 million reported in Q2 2026. Total revenue for Q2 2026 was 104,000, indicating challenges in generating income despite high gross margins.